Alpha Teknova, Sartorius BIA Separations announce collaboration

Alpha Teknova and Sartorius BIA Separations, which is part of the international life science group Sartorius, announced that the companies have entered into a collaboration arrangement that will help gene therapy companies streamline the downstream purification process. The collaboration highlights two essential components necessary for the successful recovery of empty and full AAV capsids during anion-exchange purification: the separation technology and the buffer composition. With Sartorius BIA Separations’ proprietary AAV platform designed to optimize the separation of viral particles, and Teknova’s custom, high-quality buffer solutions developed to maximize capsid enrichment, the companies conducted a robust design of experiment and successfully created a screening kit with optimized buffer formulations that drive consistency and increased purity when paired with the BIA CIMmultus QA monolith. "We’re thrilled to find a like-minded partner with Sartorius BIA Separations, a well-respected, global leader in monolith-based technologies who shares our vision of making solutions possible," said Stephen Gunstream, Teknova’s President and Chief Executive Officer. "Through our collaboration, we’re finding new tools to help our customers streamline the development of AAV therapies by optimizing their purification process and increasing the yield and purity of their AAV product."